Group 1 - The China Securities Regulatory Commission (CSRC) has issued supplementary material requirements for 19 companies, including Shimai Pharmaceutical, which is required to clarify the progress of state-owned shareholder compliance with state asset management procedures [1] - The CSRC requests Shimai Pharmaceutical to provide legal opinions on several matters, including the pricing basis for past capital increases and share transfers, and whether there are any irregularities in the pricing [1] - The company must also clarify whether its business operations involve restricted foreign investment areas, particularly in relation to human stem cells and gene diagnosis and treatment technologies [1] Group 2 - The company, established in 2017, is a pioneer in next-generation T-cell engagers (TCE) therapy and a global leader in this field [2] - TCEs are designed to simultaneously bind to tumor-associated antigens on cancer cells and receptors on T-cells, directing them to tumor tissues to activate T-cells for targeted cytotoxic effects [2] - The company has developed innovative clinical-stage products, including a next-generation TCE that can be selectively activated in tumors for the treatment of solid tumors [2]
新股消息 | 时迈药业拟港股上市 中国证监会要求补充说明国资管理程序进展情况等事项
智通财经网·2025-12-26 12:51